Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuyan Meng

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Cancer|February 6, 2019
First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive diseaseQinghua Xu, Hui Liu, Shuyan Meng, et al.
Medical Oncology (Northwood, London, England)|July 21, 2010
Integrin-targeted paclitaxel nanoliposomes for tumor therapyShuyan Meng, Bo Su, Wei Li, et al.
Nanotechnology|September 21, 2010
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomesShuyan Meng, Bo Su, Wei Li, et al.
Journal of Nanoscience and Nanotechnology|July 26, 2011
Magnetic resonance imaging contrast agent: cRGD-ferric oxide nanometer particle and its role in the diagnosis of tumorXianghua Yi, Yongmei Ding, Yu Zeng, et al.
Nanoscale Research Letters|November 29, 2018
Dual integrin αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance ImagingYin Song, Wei Li, Shuyan Meng, et al.
European Journal of Radiology|February 15, 2011
RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studiesWei Li, Bo Su, Shuyan Meng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Cell Discovery|November 25, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005)Fenghuan Sun, Lele Zhang, Liangdong Sun, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Cancer|February 6, 2019
First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive diseaseQinghua Xu, Hui Liu, Shuyan Meng, et al.
Medical Oncology (Northwood, London, England)|July 21, 2010
Integrin-targeted paclitaxel nanoliposomes for tumor therapyShuyan Meng, Bo Su, Wei Li, et al.
Nanotechnology|September 21, 2010
Enhanced antitumor effect of novel dual-targeted paclitaxel liposomesShuyan Meng, Bo Su, Wei Li, et al.
Journal of Nanoscience and Nanotechnology|July 26, 2011
Magnetic resonance imaging contrast agent: cRGD-ferric oxide nanometer particle and its role in the diagnosis of tumorXianghua Yi, Yongmei Ding, Yu Zeng, et al.
Nanoscale Research Letters|November 29, 2018
Dual integrin αvβ 3 and NRP-1-Targeting Paramagnetic Liposome for Tumor Early Detection in Magnetic Resonance ImagingYin Song, Wei Li, Shuyan Meng, et al.
European Journal of Radiology|February 15, 2011
RGD-targeted paramagnetic liposomes for early detection of tumor: in vitro and in vivo studiesWei Li, Bo Su, Shuyan Meng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2023
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLCLei Wang, Yongzhong Luo, Shengxiang Ren, et al.
Cell Discovery|November 25, 2025
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I‒III small-cell lung cancer: a phase 2 trial (LungMate-005)Fenghuan Sun, Lele Zhang, Liangdong Sun, et al.
Pageof 2